Everyone lives only once ...
and is entitled to have a splendid life.
A healthy life is not only a duty or a lifestyle attitude,
but is also a commitment made to loved ones.
For the commitment to your health,
we pledge ourselves to provide lifelong care.
Founded in 2004,
Hailing Pharma has always been committed to the development,
production, and distribution of high-quality,
safe, and effective pharmaceutical products.
Currently, it owns a number of subsidiaries
in Hainan, Shanghai, Hong Kong, Hunan, and Tibet, etc.
In January 2016, Hailing Pharma became a holding subsidiary
of Changjiang Runfa Group,
which is one of top 500 private companies in China,
and its total assets exceeded 3.8 billion RMB.
On November 18, 2016, Hailing Pharma became
a publicly listed company on the Shenzhen Stock Exchange.
Hailing Pharma now serves as the flagship company
under Changjiang Runfa's ambitious strategic plan
in the healthcare industry.
It is a high-tech enterprise with four modern manufacturing plants
of raw materials and preparations,
and all manufacturing plants have already passed the China GMP certification.
It has over 130 different pharmaceutical products and certificates,
such as powder injection, freeze-dried powder injection, small volume injection,
tablets, capsules, granules, and others,
including anti-infective drugs, cardiovascular drugs, digestive system drugs,
nervous system drugs, diabetes, and dermatologic products, etc.
In order to pursue top quality, Hailing Pharma started to adopt the U.S. cGMP,
current Good Manufacturing Practice Standards,
and implemented a world-class quality management system, QMS.
The new QMS covers every aspect of its operations,
such as product development, raw material inspection,
production process, quality control, warehouse management, logistics, and customer service.
Hailing Pharma staff scrutinize every detail during the production.
With this world-class quality standard,
Hailing Pharma ensures all the pharmaceutical products enter the market
with high brand reputation and provide the health protection to all the people.
Hailing Pharma dedicated significant resources
to new pharmaceutical product research and development
and recruited leading talent and experts
to build innovation technology platform.
The company has also built an extensive partnership
with distinguished R&D institutions, universities,
and pharmaceutical manufacturers in domestic China, America, Japan, Canada, and India, etc.
Building on continuous learning of cutting-edge technology,
Hailing Pharma's R&D team keeps developing innovative pharmaceutical products
with proprietary intellectual property and strong performance.
In recent years, Hailing Pharma has successfully applied
for a number of national invention patents
and has obtained multiple clinical trial approvals.
In addition, significant breakthroughs have been achieved
in the fields of anti-infection and oncology.
Hailing Pharma owns over 30 sales and marketing offices,
and its sales network covers more than 4,000 secondary
and tertiary-level hospitals in 31 provinces,
municipalities, and autonomous regions.
The market share goes up year by year.
According to data from MENET,
under the former CFDA Southern Medicine Economic Research Institute,
Hailing Pharma is ranked second in domestic antibiotic market.
Two core products of Hailing Pharma,
Ceftazidime for injection,
and latamoxef sodium for injection,
are listed second and fifth respectively
in the domestic antibiotics market.
Forging ahead more than a decade,
every Hailing Pharma staff put their dedication into their daily work
and make great efforts to provide quality service to customers.
With the comprehensive product brand image and excellent service,
Hailing Pharma obtained great reputation in the China pharmaceutical market.
It was honored as High and New Technology Enterprise,
Science and Technology Innovation Oriented Enterprise,
Top 10 Enterprises,
Good Faith Demonstration Enterprise in Hainan Province,
Top 100 Enterprises in China Pharmaceutical Industry,
High Growth Chinese Top 50 of Pharmaceutical Industry,
and Top 100 Enterprises of Hainan Province.
Now, Hailing Pharma has successfully built up the high reputation
and strong brand image in the China pharmaceutical industry.
Over the past few years,
Hailing Pharma invested RMB 200 million
in the construction of aseptic,
freeze-dried production facilities in Hainan
under U.S. cGMP standards.
It plans to build another first-class manufacturing plant,
specializing in the production of anti-infection and oncology products.
Hailing Pharma is now actively pursuing opportunities
to export APIs and preparations
with high added value to European and American pharmaceutical markets.
In the near future, Hailing Pharma will go beyond China
and become one of the leaders in global pharmaceutical industry.
With a heart of craftsmen to care for the livelihood,
with a spirit of benevolence to march all over the world,
adhering to the tireless pursuit of caring people's health,
Hailing Pharma will keep building a leading healthcare industrial platform in China
and will dedicate itself to human health services.
Hailing Pharma cares for life.